Valid concern! From the Ann: Investor Webinar Presentation on the 17/11/21 they stated:
Mind you this includes both the FIH trial for Alzheimer's and the FIP trial for Glaucoma. It would be very disappointing should a CR be required before either of these outcomes. $3m spend in the last quarter on pre-clinical activities seems high, lets hope some of this is upfront expenditure for the trials
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-4
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
